476 related articles for article (PubMed ID: 35244787)
21. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity.
Carija A; Pinheiro F; Pujols J; Brás IC; Lázaro DF; Santambrogio C; Grandori R; Outeiro TF; Navarro S; Ventura S
Redox Biol; 2019 Apr; 22():101135. PubMed ID: 30769283
[TBL] [Abstract][Full Text] [Related]
22. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
[TBL] [Abstract][Full Text] [Related]
23. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
24. Phase separation and other forms of α-Synuclein self-assemblies.
Poudyal M; Sakunthala A; Mukherjee S; Gadhe L; Maji SK
Essays Biochem; 2022 Dec; 66(7):987-1000. PubMed ID: 36373662
[TBL] [Abstract][Full Text] [Related]
25. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells.
Cascella R; Chen SW; Bigi A; Camino JD; Xu CK; Dobson CM; Chiti F; Cremades N; Cecchi C
Nat Commun; 2021 Mar; 12(1):1814. PubMed ID: 33753734
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of alpha-synuclein toxicity: An update and outlook.
Brás IC; Xylaki M; Outeiro TF
Prog Brain Res; 2020; 252():91-129. PubMed ID: 32247376
[TBL] [Abstract][Full Text] [Related]
27. A glimpse into the structural properties of α-synuclein oligomers.
Santos J; Pallarès I; Ventura S
Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360
[TBL] [Abstract][Full Text] [Related]
28. Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.
Nors Perdersen M; Foderà V; Horvath I; van Maarschalkerweerd A; Nørgaard Toft K; Weise C; Almqvist F; Wolf-Watz M; Wittung-Stafshede P; Vestergaard B
Sci Rep; 2015 May; 5():10422. PubMed ID: 26020724
[TBL] [Abstract][Full Text] [Related]
29. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
30. Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.
Sorrentino ZA; Hass E; Vijayaraghavan N; Gorion KM; Riffe CJ; Dhillon JS; Giasson BI
Neurosci Lett; 2020 Jul; 732():135017. PubMed ID: 32371157
[TBL] [Abstract][Full Text] [Related]
31. Carboxy-terminal truncations of mouse α-synuclein alter aggregation and prion-like seeding.
Sorrentino ZA; Xia Y; Gorion KM; Hass E; Giasson BI
FEBS Lett; 2020 Apr; 594(8):1271-1283. PubMed ID: 31912891
[TBL] [Abstract][Full Text] [Related]
32. Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein.
Leitão ADG; Rudolffi-Soto P; Chappard A; Bhumkar A; Lau D; Hunter DJB; Gambin Y; Sierecki E
Commun Biol; 2021 Sep; 4(1):1124. PubMed ID: 34556785
[TBL] [Abstract][Full Text] [Related]
33. The 3D structure of lipidic fibrils of α-synuclein.
Frieg B; Antonschmidt L; Dienemann C; Geraets JA; Najbauer EE; Matthes D; de Groot BL; Andreas LB; Becker S; Griesinger C; Schröder GF
Nat Commun; 2022 Nov; 13(1):6810. PubMed ID: 36357403
[TBL] [Abstract][Full Text] [Related]
34. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
35. Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex.
Boutros SW; Raber J; Unni VK
J Parkinsons Dis; 2021; 11(3):1091-1115. PubMed ID: 34057097
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts.
Ardah MT; Ghanem SS; Abdulla SA; Lv G; Emara MM; Paleologou KE; Vaikath NN; Lu JH; Li M; Vekrellis K; Eliezer D; El-Agnaf OMA
BMC Complement Med Ther; 2020 Mar; 20(1):73. PubMed ID: 32143619
[TBL] [Abstract][Full Text] [Related]
37. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
38. Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk.
Kayed R; Dettmer U; Lesné SE
J Parkinsons Dis; 2020; 10(3):791-818. PubMed ID: 32508330
[TBL] [Abstract][Full Text] [Related]
39. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
Kahle PJ
Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
[TBL] [Abstract][Full Text] [Related]
40. α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.
Martin ZS; Neugebauer V; Dineley KT; Kayed R; Zhang W; Reese LC; Taglialatela G
J Neurochem; 2012 Feb; 120(3):440-52. PubMed ID: 22060133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
